Prognosis
Biogen Expects Slow Alzheimer’s Drug Uptake, May Reset Price
- Company faces uproar over $56,000-a-year price tag for Aduhelm
- Biogen plans to work with Medicare for ‘budget sustainability’
This article is for subscribers only.
Biogen Inc. expects gradual uptake of its new Alzheimer’s disease drug in the U.S. and said it would consider adjusting its $56,000-a-year price if the medication is taken by more patients than anticipated.
The disclosure in a company statement Wednesday is a signal the drugmaker wants to tamp down the outcry over the treatment’s potential costs to the U.S. health-care system. The company said it set the price based on the impact of the treatment and assumptions about how many people would take it.